AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03439527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle Precursor Cells (MPCs), ATMP
Description: The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
Study NCT00794820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: 25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
Study NCT00794820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
Study NCT00794820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
Study NCT01655108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Study NCT01655108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Study NCT03855111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Acupuncture / Moxibustion
Description: Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
Study NCT03855111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized (Tailored) Active Acupuncture / Moxibustion
Description: Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
Study NCT03790930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: deep learning
Description: manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
Study NCT02312505 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: COPFX
Description: cardiac Output by semi-invasive pulse contour analysis
Study NCT03987568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
Study NCT03987568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: At the beginning of study magnetic resonance imaging MRI will be completed.
Study NCT04665193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Antigen Test
Description: Antigen Technology Lab-based test and Point of care test
Study NCT03708419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal diet
Description: Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
Study NCT02728934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Golimumab Intravenous (IV)
Description: This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
Study NCT02728934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: This is an observational study. Patients who will receive infliximab will be observed for 3 years.
Study NCT02728934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biosimilar Infliximab
Description: This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
Study NCT03167697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy
Description: Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
Study NCT01884727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Salt Water
Description: Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
Study NCT03167697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: Patients will continue their usual dietary and/or protein substitute regimen (28 days).
Study NCT04044638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance trainining
Description: Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
Study NCT00793585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
Study NCT00793585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continue their usual therapy
Description: Patients will receive lifestyle modification and continue their usual therapy.
Study NCT01884727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ASEA water
Description: Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
Study NCT02219243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Interpretation Training Condition 1
Description: The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
Study NCT02219243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Interpretation Training Condition 2
Description: The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
Study NCT02189954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The placement according to the manufacturer's instructions
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
Study NCT02189954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cuff inner pressure was held below 44 mmHg
Description: cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
Study NCT01789918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARADISE percutaneous renal denervation
Description: Intravascular ultrasound emission
Study NCT03835728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
Study NCT03835728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This will be the matching placebo used in the study.
Study NCT04331197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg
Description: Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Study NCT03747276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Trial Kiosk
Description: Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
Study NCT00137735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300mg tds
Study NCT00137735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tds
Study NCT02718963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study NCT03683667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Product
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
Study NCT03683667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Contain inert excipients only
Study NCT03683667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only
Study NCT03683667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
Study NCT03708419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboptimal diet
Description: The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above.
Study NCT04262141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-7289
Description: Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
Study NCT00432133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protection Motivation Theory-Based Intervention
Description: Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
Study NCT03683667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Supplement
Description: Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
Study NCT03683667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric Supplement
Description: Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
Study NCT03683667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg
Description: Egg provided daily to infants from 6-12 months of age
Study NCT03683667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding
Study NCT00432133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmenta
Description: Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
Study NCT03683667 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding
Study NCT04331197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Study NCT00056056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Description: The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
Study NCT00056056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxypsoralen
Description: The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
Study NCT00056056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methoxypsoralen
Description: The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
Study NCT00056056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV light therapy
Description: Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
Study NCT00056056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UV light therapy
Description: Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
Study NCT03101267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: Intradermal vaccination at 2-week intervals
Study NCT03101267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal vaccination at 2-week intervals
Study NCT03195296 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention related to the study is foreseen
Study NCT03464565 — intervention group
Intervention type: DEVICE
Intervention: Penumbra System
Description: Penumbra System
Study NCT02218177 — intervention group
Intervention type: DRUG
Intervention: Aflibercept
Description: anti-VEGF treatment for wet age related macular degeneration
Study NCT02218177 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: anti-VEGF treatment for wet age related macular degeneration
Study NCT02218177 — intervention group
Intervention type: PROCEDURE
Intervention: Combination Photodynamic Therapy
Description: Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
Study NCT00649961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin injection
Description: A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.
Study NCT00936091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A supplements
Description: gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 0.1 mg
Description: 0.1 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 0.5 mg
Description: 0.5 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 2.5 mg
Description: 2.5 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 10 mg
Description: 10 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 50 mg
Description: 50 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 150 mg
Description: 150 mg of JNJ-64140284 will be administered as an oral solution.
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 (dose to be determined [TBD])
Description: JNJ-64140284 (dose to be determined) will be administered as an oral solution.
Study NCT00936091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 children received placebo capsules
Study NCT04168632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMAT
Description: The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
Study NCT00801671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cPAP
Description: After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
Study NCT00801671 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cPAP
Description: After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
Study NCT00941577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR645
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study NCT00941577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study NCT05158647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
Study NCT05158647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: 10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
Study NCT03139942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical spectral reflectance and autofluorescence imaging
Description: When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
Study NCT01456377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: predinose oral
Description: 1 mg for kg for 3 wekees
Study NCT01456377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: use a oral placebo